Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Vaughn Kailian
AddedMar 31, 2024
UpdatedMay 31, 2026
Vaughn Kailian

Vaughn Kailian

Board Member, Cephalon

Crunchbase

Vaughn Kailian's Career

Cephalon
Cephalon

Malvern, PA, US

Board Member· Board
Cerimon Pharmaceuticals
Cerimon Pharmaceuticals

South San Francisco, CA, US

Board Member· Board
Vascular Pharmaceuticals
Vascular Pharmaceuticals

Chapel Hill, NC, US

Board Member· Board
Xanodyne Pharmaceuticals
Xanodyne Pharmaceuticals

Newport, KY, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Vaughn Kailian's Career

Cephalon
Cephalon
Acquired01987Malvern, PA, US
Board Member· Board

Leadership at Cephalon

Charles HomcyCharles HomcyBoard Member
William P Egan \"Bill\"William P Egan \"Bill\"Board Member
Kevin MoleyKevin MoleyBoard Member
Frank BaldinoFrank BaldinoFounder
Martyn GreenacreMartyn GreenacreBoard Member

Similar to Cephalon

NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
TrevenaTrevenaKing of Prussia, PA, USPharmaceuticalsest. 2007TrevenaKing of Prussia, PA, US · est. 2007

Trevena: A biopharmaceutical firm innovating novel CNS disorder treatments.

Public · $473.7M35
Supernus PharmaceuticalsSupernus PharmaceuticalsRockville, MD, USPharmaceuticalsest. 2005Supernus PharmaceuticalsRockville, MD, US · est. 2005

US-based Supernus Pharmaceuticals develops and markets proprietary drugs for central nervous system disorders.

Public · $689.5M612
UCBUCBCity of Brussels, Flemish Brabant, BEPharmaceuticalsest. 1928UCBCity of Brussels, Flemish Brabant, BE · est. 1928

Belgium-based UCB SA is a global biopharmaceutical firm specializing in CNS disorders and inflammatory diseases.

Public · $195.3M7.6k
Cerimon Pharmaceuticals
Cerimon Pharmaceuticals
Public$72.7M302004South San Francisco, CA, US
Board Member· Board

Leadership at Cerimon Pharmaceuticals

Paul HastingsPaul HastingsBoard Member
James ShannonJames ShannonBoard Member
Pollard Scots-KnightPollard Scots-KnightBoard Member

Similar to Cerimon Pharmaceuticals

Cerium PharmaceuticalsCerium PharmaceuticalsGaithersburg, MD, USPharmaceuticalsest. 2012Cerium PharmaceuticalsGaithersburg, MD, US · est. 2012

Cerium Pharmaceuticals: Developing and commercializing medicines for rare diseases.

Series A · $13.1M9
Ceramedix HoldingCeramedix HoldingNew York City, NY, USBiotherapeuticsest. 2020Ceramedix HoldingNew York City, NY, US · est. 2020

Ceramedix Holding, a NYC-based medical firm, develops antibody-based drugs for novel diseases.

Seed · $3M5
Marillion PharmaceuticalsMarillion PharmaceuticalsExton, PA, USDrugs, Therapeuticsest. 2005Marillion PharmaceuticalsExton, PA, US · est. 2005

Marillion Pharmaceuticals: Innovating and commercializing therapeutics for cancer and autoimmune diseases across the US.

Public · $500k5
NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
Vascular Pharmaceuticals
Vascular Pharmaceuticals
Series B$29M102005Chapel Hill, NC, US
Board Member· Board

Leadership at Vascular Pharmaceuticals

Phil GutryPhil GutryBoard Member
David ClemmonsDavid ClemmonsFounder
Liz StonerLiz StonerBoard Member
Richard J. SheaRichard J. SheaCEO
Xanodyne Pharmaceuticals
Xanodyne Pharmaceuticals
Acquired$307.9M02000Newport, KY, US
Board Member· Board

Leadership at Xanodyne Pharmaceuticals

Roger GriggsRoger GriggsBoard Member
Dr James S ShannonDr James S ShannonBoard Member
Roger GriggsRoger GriggsFounder

Vaughn Kailian's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Vaughn Kailian

Dan PelakDan PelakBoard Member · Vertos MedicalJohn F RyanJohn F RyanBoard Member · CardiokinetixJames NahirnyJames NahirnyFounder · Alsora CapitalPeter MertensPeter MertensBoard Member · RecogniMitchell DannMitchell DannFounder · Sapient Capital ManagementBill KrauseBill KrauseBoard Member · Sybase